View More Recent Stories

May 12, 2020 08:00AM Cue Biopharma to Host Business Update Call and Webcast
May 12, 2020 08:00AM Cue Biopharma to Host Business Update Call and Webcast
Apr 20, 2020 08:14AM Cue Biopharma Inc. (CUE) Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA as First-line Treatment For HPV+ Recurrent/Metastatic Head and Nec
Apr 20, 2020 08:00AM Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment For HPV+ Recurrent/Metastatic Head
Apr 20, 2020 08:00AM Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment For HPV+ Recurrent/Metastatic Head
Mar 17, 2020 04:05PM Cue Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
Mar 17, 2020 04:05PM Cue Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
Mar 10, 2020 08:00AM Cue Biopharma to Host Business Update Call and Webcast
Mar 10, 2020 08:00AM Cue Biopharma to Host Business Update Call and Webcast
Feb 26, 2020 08:00AM Cue Biopharma to Present at Upcoming Investor Conferences in March 2020
Feb 26, 2020 08:00AM Cue Biopharma to Present at Upcoming Investor Conferences in March 2020
Feb 19, 2020 08:00AM Cue Biopharma’s Therapeutic Immuno-STAT Platform to be Featured in Merck Presentation at Antigen-Specific Immune Tolerance Drug Development Summit
Feb 19, 2020 08:00AM Cue Biopharma’s Therapeutic Immuno-STAT Platform to be Featured in Merck Presentation at Antigen-Specific Immune Tolerance Drug Development Summit
Feb 12, 2020 08:00AM Cue Biopharma to Present at the Biomarkers Series UK
Feb 12, 2020 08:00AM Cue Biopharma to Present at the Biomarkers Series UK
Jan 21, 2020 08:08AM Cue Biopharma Inc. (CUE) Announces Publication in Clinical Cancer Research of Preclinical and Translational Data Supporting the Therapeutic Potential of CUE-101 in HPV16-Related Malignancies
Jan 21, 2020 08:00AM Cue Biopharma Announces Publication in Clinical Cancer Research of Preclinical and Translational Data Supporting the Therapeutic Potential of CUE-101 in HPV16-Related Malignancies
Jan 21, 2020 08:00AM Cue Biopharma Announces Publication in Clinical Cancer Research of Preclinical and Translational Data Supporting the Therapeutic Potential of CUE-101 in HPV16-Related Malignancies
Dec 2, 2019 08:00AM Cue Biopharma to Present at the World Vaccine & Immunotherapy Congress
Dec 2, 2019 08:00AM Cue Biopharma to Present at the World Vaccine & Immunotherapy Congress
Nov 12, 2019 04:00PM Cue Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights
Nov 12, 2019 04:00PM Cue Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights
Nov 6, 2019 08:00AM Cue Biopharma to Present at Upcoming Investor Conferences in November 2019
Nov 6, 2019 08:00AM Cue Biopharma to Present at Upcoming Investor Conferences in November 2019
Nov 5, 2019 08:00AM Cue Biopharma to Host Business Update Call and Webcast
Nov 5, 2019 08:00AM Cue Biopharma to Host Business Update Call and Webcast
Oct 30, 2019 08:00AM Cue Biopharma Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
Oct 30, 2019 08:00AM Cue Biopharma Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
Oct 15, 2019 08:00AM Cue Biopharma to Present at the Oppenheimer Houston Oncology Summit at the University of Texas MD Anderson Cancer Center
Oct 15, 2019 08:00AM Cue Biopharma to Present at the Oppenheimer Houston Oncology Summit at the University of Texas MD Anderson Cancer Center
Oct 9, 2019 04:32PM Cue Biopharma Inc. (CUE) Appoints Aaron Fletcher Ph.D.; Anthony DiGiandomenico to Step Down
Oct 9, 2019 04:30PM Cue Biopharma Announces Changes to its Board of Directors
Oct 9, 2019 08:00AM Cue Biopharma to Present at Upcoming October 2019 Scientific Conferences
Oct 7, 2019 04:30PM Cue Biopharma Promotes Dr. Anish Suri to President and CSO
Oct 2, 2019 08:00AM Cue Biopharma to Present Corporate Overview and Update on Clinical Development Progress for CUE-101 at the Cantor 2019 Global Healthcare Conference
Sep 30, 2019 08:05AM Cue Biopharma Inc. (CUE) Begins Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma
Sep 30, 2019 08:00AM Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma
View More Recent Stories